Biopharm Reports publishes new market findings on current practices, developments, trends, growth, shrinkage and opportunities in the cancer molecular diagnostics field, including the use of Next-Generation Sequencing (NGS).
Next-Generation Sequencing (NGS) is one of the most rapidly growing techniques in cancer diagnostics.
Online PR News – 27-January-2014 –Next-Generation Sequencing (NGS) has seen dramatic advances in recent years and this month Illumina, the leading developer of DNA sequencers, announced they had reached a major milestone with the introduction of an instrument that can sequence a human genome in one day for just one $1,000. Increasingly, NGS is being used in the cancer field, where it offers powerful diagnostic and prognostic capabilities, as well as insights into new cancer drug targets. Indeed, NGS has now advanced to the point where it is being increasingly considered for routine cancer diagnostics, not least because NGS allows the identification of multiple genetic variations in this disease, which is increasingly recognised as fundamental to more personalised therapeutic strategies.
A new market study of cancer Molecular Diagnostics is published this month by Biopharm Reports. This study, which involved the participation of 596 cancer physicians and research scientists, investigated the use of different molecular techniques, their applications, as well as molecular biomarkers and other key areas. While this study shows that cancer diagnostics is dominated by techniques such as immunohistochemistry, imaging and established PCR methodologies, it also found that that the most rapidly developing diagnostic areas are Next-Generation Sequencing (NGS), Mass Spectrometry (MS), Microarray and the study of Circulating Tumour Cells (CTCs) and Cancer Stem Cells (CSCs).
Biopharm Reports carries out market studies of techniques, methods, and instrumentation used in life science and clinical laboratories. These are conducted through specialist groups of experienced end-users and practitioners, and therefore findings are based on 'real world' market data.